** Shares of therapy developer Immuneering rise 101.7% to $4.76 premarket
** Co says its therapy, IMM-1-104, showed an overall response rate of 43% in combination with gemcitabine during a mid-stage trial for patients with pancreatic cancer
** IMRX will expand the trial to include three combination treatment arms this year in addition to the existing three arms
** Co says it expects further trial data in Q2 2025
** Up to last close, stock down 64.8% in the previous 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.